The American Heart Association, in collaboration with its Center for Health Technology and Innovation, has announced the selection of eight companies to join the Heart and Brain Health Accelerator. This initiative is part of the broader MedTech Innovator Accelerator Program and focuses on supporting companies with groundbreaking medical or digital health technologies that align with the Association's mission to combat heart disease and stroke.
Among the selected companies, Kelvin Health stands out for its use of mobile thermal imaging and AI to diagnose vascular diseases non-invasively. Similarly, LightHearted AI Health is developing a contactless biometric device for heart condition detection, aiming to make diagnostics more accessible. MOMM Diagnostics is working on a rapid blood test for early detection of preeclampsia in pregnancy, showcasing the diverse range of innovations supported by the program.
Other participants include Powerful Medical, which leverages AI for ECG interpretation, and Reach Neuro, developing an implantable device to aid stroke recovery. Sinaptica Therapeutics and SynchNeuro are focusing on non-invasive therapies for Alzheimer's and blood sugar monitoring, respectively, while Veravas is innovating in biomarker purification for disease detection.
These companies will benefit from mentorship, funding, and networking opportunities through the MedTech Innovator program, with a chance to compete in the MedTech Innovator Competition Finals. The initiative underscores the American Heart Association's commitment to fostering technologies that promise to transform care for heart and brain health conditions, making significant strides towards healthier lives worldwide.
